Similar articles

• [Tris-(hydroxymethyl)aminomethane (THAM) for therapy of acidosis in children].

  Vercruysse G, Weissenbacher G, Zweymüller E. Vercruysse G, et al. Acta Otolaryngol. 1966 Jun 27:765-74. Acta Otolaryngol. 1966. PMID: 4966923 German. No abstract available.
• [Contribution on the hyaline membrane syndrome in premature and newborn infants].

  Hächl G, Hohenauer L. Hächl G, et al. Wien Klin Wochenschr. 1968 Aug 2;80(31):589 passim. Wien Klin Wochenschr. 1968. PMID: 5709330 German. No abstract available.
• [The use of THAM (2-amino-2-hydroxymethyl-1,3-propanediol) in corrections of respiratory and metabolic acidosis].

  Aletti L, Minetto E, Maritano M. Aletti L, et al. Minerva Anestesiol. 1966 May;32(5):272-81. Minerva Anestesiol. 1966. PMID: 5964312 Italian. No abstract available.
• Tris buffer (THAM). An appraisal of its physiologic effects and clinical usefulness.

  Bleich HL, Schwartz WB. Bleich HL, et al. N Engl J Med. 1966 Apr 7;274(14):782-7. doi: 10.1056/NEJM196604072741407. N Engl J Med. 1966. PMID: 17926886 Review.
• [Hyaline membrane disease].

  Yunes-Zárraga JL, Rodríguez-Aguilar DF, Velázquez-Quintana N, Villanueva-Salinas J. Yunes-Zárraga JL, et al. Bol Med Hosp Infant Mex. 1993 Apr;50(4):284-93. Bol Med Hosp Infant Mex. 1993. PMID: 8471176 Review. Spanish. No abstract available.